High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction: Results from TIMI (thrombolysis in myocardial infarction) 14 Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Immunoglobulin Fab Fragments
  • Myocardial Infarction
  • Plasminogen Activators
  • Platelet Aggregation
  • Platelet Aggregation Inhibitors
  • Thrombolytic Therapy
  • Tissue Plasminogen Activator

abstract

  • Platelet activation and aggregation are heightened in the setting of thrombolysis for AMI. Despite this enhanced level of platelet activation, abciximab, combined with a reduced-dose thrombolytic, inhibited platelet aggregation similarly to the level reported in elective settings.

publication date

  • June 13, 2000

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 10851205

Additional Document Info

start page

  • 2690

end page

  • 5

volume

  • 101

number

  • 23